ClinicalTrials.gg

Program

SHR-1703

A development code. Also written as “SHR-1703 Injection”.

In Jiangsu HengRui Medicine's pipeline, IL-5. Its studies are mostly in Asthma · Churg-Strauss Syndrome, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Jul 30, 20237 company-led studies, 3 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine73 open or runningphase 3since Jul 30, 2023Jul 15, 2020Apr 2027phase 1 · NCT07701239
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-1703, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 15, 2020First study: phase 1 study in AsthmaFirst studyNCT04480762 · 42 enrolled · China
  2. Apr 20, 2021Phase 1 study in AsthmaNCT04855591 · 1 enrolled · Australia
  3. Jul 20, 2021Phase 1 study in AsthmaNCT05042401 · 23 enrolled · China
  4. Aug 29, 2022Phase 2 study in Asthma With Eosinophilic PhenotypeNCT05522439 · 85 enrolled · China
  5. Jul 30, 2023Phase 3 study in Churg-Strauss SyndromeNCT05979051 · 166 planned · China
  6. May 29, 2024Phase 2 study in Eosinophilic Asthma PatientsNCT06441812 · 200 planned · China
  7. Jul 9, 2026Phase 1 study in Asthma With Eosinophilic PhenotypeNCT07701239 · 84 planned · China

Ahead

  1. Apr 2027Primary completion: phase 1 study in Asthma With Eosinophilic PhenotypeNCT07701239
  2. Sep 2028Primary completion: phase 2 study in Eosinophilic Asthma PatientsNCT06441812
  3. Dec 2028Primary completion: phase 3 study in Churg-Strauss SyndromeNCT05979051

TargetBeta

“IL-5”the company's pipeline, read by Claude · source

Other programs on IL5

ProgramCompanyFurthest phaseStudies
depemokimabruleGlaxoSmithKlinephase 418

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07701239Asthma With Eosinophilic Phenotype · China1Not yet recruitingApr 202784
NCT06441812Eosinophilic Asthma Patients · China2RecruitingSep 2028200
NCT05979051Churg-Strauss Syndrome · China3RecruitingDec 2028166
NCT05522439Asthma With Eosinophilic Phenotype · China2CompletedSep 12, 202485
NCT05042401Asthma · China1UNKNOWNJun 15, 202323
NCT04855591Asthma · Australia1TerminatedSep 13, 20211
NCT04480762Asthma · China1CompletedSep 21, 202142

How it is read

Names in the registry

  • “SHR-1703”, 6 entries
  • “SHR-1703 Injection”, 3 entries

Codes read as this program: SHR1703.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.